Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,208 JPY
Change Today +13.00 / 1.09%
Volume 79.7K
4514 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

aska pharmaceutical co ltd (4514) Snapshot

Open
¥1,194
Previous Close
¥1,195
Day High
¥1,209
Day Low
¥1,183
52 Week High
09/29/14 - ¥1,500
52 Week Low
05/15/14 - ¥772.00
Market Cap
36.9B
Average Volume 10 Days
61.3K
EPS TTM
¥24.99
Shares Outstanding
30.6M
EX-Date
03/27/15
P/E TM
48.3x
Dividend
¥14.00
Dividend Yield
1.16%
Current Stock Chart for ASKA PHARMACEUTICAL CO LTD (4514)

Related News

No related news articles were found.

aska pharmaceutical co ltd (4514) Related Businessweek News

No Related Businessweek News Found

aska pharmaceutical co ltd (4514) Details

ASKA Pharmaceutical Co., Ltd. is engaged in the manufacture, sale, and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices. The company offers Altat for the treatment of digestive ulcers and gastritis; Prostal, a drug for the treatment of benign prostatic hypertrophy and prostate cancer; Calcitoran, a synthetic salmon calcitonin formulation; Lipidil, an antihyperlipidemic agent; and Thyradin, a drug for the treatment of hypothyroidism. In addition, it is developing BNP7787, an antineoplastic effect enhancer for antineoplastic drugs, which is in Phase III clinical trials in Europe, the United States, and Japan; and AKP-501, an infertility medication containing the genetically modified follicle-stimulating hormone. ASKA Pharmaceutical Co., Ltd. was founded in 1920 and is headquartered in Tokyo, Japan.

886 Employees
Last Reported Date: 06/27/14
Founded in 1920

aska pharmaceutical co ltd (4514) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

aska pharmaceutical co ltd (4514) Key Developments

ASKA Pharmaceutical Co.Ltd. to Report Q3, 2015 Results on Feb 04, 2015

ASKA Pharmaceutical Co.Ltd. announced that they will report Q3, 2015 results on Feb 04, 2015

ASKA Pharmaceutical Co.Ltd. to Report Q2, 2015 Results on Nov 04, 2014

ASKA Pharmaceutical Co.Ltd. announced that they will report Q2, 2015 results on Nov 04, 2014

ASKA Pharmaceutical Co.Ltd. to Report Q1, 2015 Results on Aug 04, 2014

ASKA Pharmaceutical Co.Ltd. announced that they will report Q1, 2015 results on Aug 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4514:JP ¥1,208.00 JPY +13.00

4514 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4514.
View Industry Companies
 

Industry Analysis

4514

Industry Average

Valuation 4514 Industry Range
Price/Earnings 48.2x
Price/Sales 0.8x
Price/Book 0.9x
Price/Cash Flow 51.8x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASKA PHARMACEUTICAL CO LTD, please visit www.aska-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.